MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598745 | Name: Levormeloxifene fumarate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levormeloxifene fumarate is an osteoporosis agent and selective estrogen receptor modulator (SERM).

Chemical Structure

Levormeloxifene fumarate
CAS#199583-01-2

Theoretical Analysis

MedKoo Cat#: 598745

Name: Levormeloxifene fumarate

CAS#: 199583-01-2

Chemical Formula: C34H39NO7

Exact Mass:

Molecular Weight: 573.69

Elemental Analysis: C, 71.18; H, 6.85; N, 2.44; O, 19.52

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
199583-01-2 (fumarate) 78994-23-7 (free)
Synonym
Levormeloxifene fumarate;
IUPAC/Chemical Name
1-(2-(4-((3R,4R)-7-methoxy-2,2-dimethyl-3-phenylchroman-4-yl)phenoxy)ethyl)pyrrolidine fumarate
InChi Key
CKDZFQCZLXNLRD-JJGRXVLVSA-N
InChi Code
InChI=1S/C30H35NO3.C4H4O4/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31;5-3(6)1-2-4(7)8/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t28-,29+;/m1./s1
SMILES Code
CC1(C)[C@@H](C2=CC=CC=C2)[C@H](C3=CC=C(OCCN4CCCC4)C=C3)C5=CC=C(OC)C=C5O1.O=C(O)/C=C/C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Levormeloxifene fumarate is an osteoporosis agent and selective estrogen receptor modulator (SERM).
In vitro activity:
SMC proliferation was significantly increased by levormeloxifene [relative cell number, mean ± SE, levormeloxifene 0.1 µM 130 ± 13% of control (P=NS), 1 µM 151 ± 19% of control (P<0.05)]. Tropoelastin production was significantly decreased by levormeloxifene [mean ± SE, levormeloxifene 0.1 µM 75 ± 4% of control (P=NS), 1 µM 64 ± 2% of control (P<0.05)]. Reference: J Smooth Muscle Res. 2011;47(1):11-9. https://pubmed.ncbi.nlm.nih.gov/21757851/
In vivo activity:
Ovariectomy resulted in an increase in these markers; the increase was prevented by estradiol or levormeloxifene. Estradiol or levormeloxifene inhibited loss of lumbar spine bone mineral density (BMD) following ovariectomy compared with untreated monkeys (ovx -5.0%; sham -0.4%; est +0.2%; L1 -3.6%, L2 -2.0%, L3 -2.5%). Reference: Bone. 2001 Jul;29(1):7-15. https://pubmed.ncbi.nlm.nih.gov/11472885/

Preparing Stock Solutions

The following data is based on the product molecular weight 573.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Takacs P, Yavagal S, Zhang Y, Candiotti K, Medina CA. Levormeloxifene inhibits vaginal tropoelastin and transforming growth factor beta 1 production. J Smooth Muscle Res. 2011;47(1):11-9. doi: 10.1540/jsmr.47.11. PMID: 21757851. 2. Hotchkiss CE, Stavisky R, Nowak J, Brommage R, Lees CJ, Kaplan J. Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys. Bone. 2001 Jul;29(1):7-15. doi: 10.1016/s8756-3282(01)00465-3. PMID: 11472885. 3. Holm P, Shalmi M, Korsgaard N, Guldhammer B, Skouby SO, Stender S. A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits. Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2264-72. doi: 10.1161/01.atv.17.10.2264. PMID: 9351399.
In vitro protocol:
1. Takacs P, Yavagal S, Zhang Y, Candiotti K, Medina CA. Levormeloxifene inhibits vaginal tropoelastin and transforming growth factor beta 1 production. J Smooth Muscle Res. 2011;47(1):11-9. doi: 10.1540/jsmr.47.11. PMID: 21757851.
In vivo protocol:
1. Hotchkiss CE, Stavisky R, Nowak J, Brommage R, Lees CJ, Kaplan J. Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys. Bone. 2001 Jul;29(1):7-15. doi: 10.1016/s8756-3282(01)00465-3. PMID: 11472885. 2. Holm P, Shalmi M, Korsgaard N, Guldhammer B, Skouby SO, Stender S. A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits. Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2264-72. doi: 10.1161/01.atv.17.10.2264. PMID: 9351399.
1: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):615-43. PubMed PMID: 12616707.

View History

Lexitropsin

Lexitropsin

Lexaptepid pegol

Lexaptepid pegol

Cofrogliptin

Cofrogliptin